Advancements in Atopic Dermatitis: Insights from the 2024 Masterclasses in Dermatology Conference

Susan Taylor, MD, shared what she wants to know about patients' functionality to treat their atopic dermatitis with hand or foot involvement.

Susan Taylor, MD, explained the current state of diversity in clinical trials, what is going well, and opportunities to improve.

Peter Lio, MD, takes a deep dive into the results of the 3 LIBERTY-AD-HAFT study and how it impacts the treatment of hand-foot atopic dermatitis.

Peter Lio, MD, expands on dosing considerations to treat atopic dermatitis with involvement on the hands and feet for different ages, weights, lifestyles, and more.

Peter Lio, MD, explains the importance of having a wide-range of solutions and how he incorporates alternative approaches alongside conventional medicine.

Raj Chovatiya, MD, PhD, gives an overview of what all clinicians need to know about the updated atopic dermatitis guidelines published by the American Academy of Dermatology including approaches with systemic therapies, which therapeutic modalities to prioritize, and patient considerations to guide decision-making.

Raj Chovatiya, MD, PhD, dissects the nomenclature of atopic dermatitis and shares the importance of understanding other conditions under the eczema umbrella.

Brad Glick, DO, MPH, emphasizes the importance of personalized and inclusive communication in choosing therapeutics for atopic dermatitis.

Brad Glick, DO, MPH, says it is essential to consider patient lifestyles when choosing atopic dermatitis therapies.

David Rosmarin, MD, addresses the research gaps in recommendations for systemic therapies in atopic dermatitis in the latest guidelines.

David Rosmarin, MD, acknowledges opportunities for further research in diverse populations to continue updating AD treatment guidelines.

Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD.